17 completed, 5 terminated, 4 recruiting, 1 active not recruiting. 28 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 17, Terminated 5, Recruiting 4, Active not recruiting 1, Suspended 1 |
| Phase 2 | 14 | Completed 7, Recruiting 4, Terminated 3 |
Follow Peanut Allergy: new trials by email Literature Review of Peanut Allergy trials Research Report on Peanut Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of MOON101 for the Treatment of Peanut Allergy Dose A, Dose B, Dose C - Peanut Allergy | Phase 1 | Suspended | Moonlight Therapeutics, Inc. | 40 | 2026-06-29 | 2026-10-16 |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
| Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants ENP-501, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | N-Fold, LLC | 68 | 2025-12-16 | 2026-04-24 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 IGNX001, Placebo - Peanut Allergy | Phase 1 | Completed | IgGenix Australia Pty Ltd | 32 | 2024-09-01 | 2025-11-14 |
| Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects VLP Peanut, Placebo - Peanut Allergy | Phase 1 | Active not recruiting | Allergy Therapeutics | 46 | 2022-10-17 | 2026-03-13 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| CNP-201 in Subjects With Peanut Allergy CNP-201, Placebo - Peanut Allergy | Phase 1 | Terminated | COUR Pharmaceutical Development Company, Inc. | 15 | 2022-03-14 | 2023-12-20 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Prebiotic, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of Chicago | 20 | 2021-11-30 | 2026-03-09 |
| Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy CNP-201, Placebo - Peanut Allergy | Phase 1 | Terminated | COUR Pharmaceutical Development Company, Inc. | 9 | 2021-06-02 | 2023-09-18 |
| OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut INT301, Placebo - Peanut Allergy | Phase 1 | Completed | Intrommune Therapeutics | 32 | 2021-05-15 | 2023-07-28 |
| Oral Immunotherapy for Peanut Allergic Patients INP20, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | InnoUp Farma S.L. | 50 | 2020-03-11 | 2025-04-30 |
| VE416 for Treatment of Food Allergy Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2019-06-28 | 2023-10-18 |
| Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy Peanut Immunotherapy - Food Allergy, Peanut Allergy | Phase 1 / Phase 2 | Terminated | University Hospital, Geneva | 12 | 2019-04-01 | 2023-08-28 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine ASP0892, Placebo - Peanut Allergy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 20 | 2019-03-12 | 2024-10-23 |
| Salvage Peanut Oral Immunotherapy Study Peanut OIT - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 15 | 2018-01-03 | 2023-01-30 |
| A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects DBV712 IHRP - Peanut Allergy | Phase 1 | Completed | DBV Technologies | 27 | 2017-11-24 | 2019-07-26 |
| Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients Fecal Microbiota Capsule - Peanut Allergy | Phase 1 | Completed | Rima Rachid | 15 | 2017-03-03 | 2026-10-08 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal - Peanut Allergy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 31 | 2016-12-13 | 2024-10-23 |
| HAL-MPE1 Safety and Tolerability Study HAL-MPE1, HAL-MPE1 placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 42 | 2016-12-01 | 2020-02-19 |
| HAL-MPE1 First-in-human HAL-MPE1, Placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 17 | 2014-06-01 | 2015-07-10 |
Showing 20 of 28. Sign in to see all of them.
Peanut Hypersensitivity (28) · Food Hypersensitivity (10) · Hypersensitivity (3) · Anaphylaxis (2) · Hypersensitivity, Immediate (1)
Immune System Diseases (28) · Nut and Peanut Hypersensitivity (28) · Hypersensitivity, Immediate (27) · Hypersensitivity (25) · Food Hypersensitivity (18)
Omalizumab (2) · Fecal Microbiota Transplantation (1) · Prebiotics (1) · Vancomycin (1)
University of North Carolina, Chapel Hill (3) · Astellas Pharma Global Development, Inc. (2) · COUR Pharmaceutical Development Company, Inc. (2) · DBV Technologies (2) · HAL Allergy (2) · Massachusetts General Hospital (2) · ALK-Abelló A/S (1) · Allergy Therapeutics (1) · Boston Children's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1) · IgGenix Australia Pty Ltd (1) · InnoUp Farma S.L. (1) · Intrommune Therapeutics (1) · Johns Hopkins University (1) · Lynda Schneider (1)
United States (22) · Australia (2) · Canada (2) · Denmark (1) · New Zealand (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Edwin Kim, MD (3) · Jerry Staser (2) · Robert Wood, MD (2) · Wayne G Shreffler, MD, PhD (2) · Wesley Burks, MD (2) · Ana Tabar, PhD, MD (1) · Andrew MacGinnitie, MD, PhD (1) · Andrew T Clark, MB BD MD (1) · Brian P Vickery, MD (1) · Carsten Bindslev-Jensen, Prof. Dr. (1) · Christina E Ciaccio, MD (1) · Corinne Keet, MD, MS (1) · Hugh Sampson, MD (1) · Jacqueline Pongracic, MD (1) · Jean-Christoph Caubet, MD (1)
PMID 32414772, PMID 33463542, PMID 38010254, PMID 19226304, PMID 21414048, PMID 26920463, PMID 29700872, PMID 31676085, PMID 34755130, PMID 34813505, PMID 39756833, PMID 39842774
2018 (1), R01AT004435 (1), U19AI095261 (1), U44AI165328 (1)